Focus: Sanofi is a Paris-based Big Pharma with 91,000 employees specializing in small molecules and biologics across immunology, oncology, neurology, rare diseases, and vaccines. It is a publicly traded company (SNY) with significant global scale and market presence.
Profile data last refreshed 18h ago · AI intelligence enriched 2mo ago
Hot — 1200 jobs added in 30d
Net +329 (1200 new, 871 removed). Aggressive expansion phase.
Sanofi is a stable global pharma employer suitable for established-career professionals seeking scale and geographic diversity, but faces significant patent cliff risk and pipeline modernization pressure.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Sanofi's cash cow, generating nearly half of total revenue, with loss of exclusivity imminent and generic competition accelerating.
Help build intelligence for Sanofi
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Sanofi's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Extended-release formulation of LANTUS SOLOSTAR facing similar patent cliff pressures and declining revenue trajectory.
Higher-concentration insulin glargine variant at peak sales; provides some portfolio diversification within the insulin franchise.
Ultra-concentrated formulation supporting premium positioning; contributes to sustained insulin franchise revenue but faces same structural LOE risks.
Cardiac arrhythmia therapy with 2031 LOE; second-highest revenue at-risk product and a key patent cliff exposure.
Orphan-designated ACTH analog with unique MOA; approaching LOE with limited pipeline alternatives in this indication.
MS disease-modifying therapy at peak sales with extended LOE window (2034), providing medium-term revenue stability.
Recently approved rare disease therapy with longest LOE horizon (2042) in the portfolio; growth potential in hematology-oncology.
Nephrology-focused therapy with 2030 LOE; part of $523M cumulative patent cliff exposure over next decade.
Duplicate entry reflecting uncertain LOE timing; underscores portfolio uncertainty in renal disease segment.
225 discontinued, 25 duplicate formulations not shown
+16 more products with revenue data
Sanofi’s Regret: Hanmi Emerges as Global Obesity Drug Leader - 동아비즈니스리뷰 | DBR
Sanofi’s Regret: Hanmi Emerges as Global Obesity Drug Leader 동아비즈니스리뷰 | DBR
Sanofi shortfall shifts flu shots to NIP as South Korea faces private-market squeeze - CHOSUNBIZ - Chosunbiz
Sanofi shortfall shifts flu shots to NIP as South Korea faces private-market squeeze - CHOSUNBIZ Chosunbiz
Sanofi stock holds large-cap valuation as latest figures highlight consumer healthcare strength - AD HOC NEWS
Sanofi stock holds large-cap valuation as latest figures highlight consumer healthcare strength AD HOC NEWS
Sanofi symposium challenges ‘last resort’ view of insulin therapy - Korea Biomedical Review
Sanofi symposium challenges ‘last resort’ view of insulin therapy Korea Biomedical Review
Belén Garijo Says Sanofi Has “No Target Number” for Pipeline Cuts as Big Pharma’s Q2 Masks a Looming Cliff - finance.biggo.com
Belén Garijo Says Sanofi Has “No Target Number” for Pipeline Cuts as Big Pharma’s Q2 Masks a Looming Cliff finance.biggo.com
Astellas, Takeda, Sanofi, Accord BioPharma, CMI Media Group Lead Insights at our Pharma & Health Brand Insider Summit - MediaPost
Astellas, Takeda, Sanofi, Accord BioPharma, CMI Media Group Lead Insights at our Pharma & Health Brand Insider Summit MediaPost
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent peer-reviewed publications with author affiliations at this company
NAStructuralDB : structural database to facilitate computational studies of molecular modeling and recognition of proteins with special focus on antibody-antigen interactions.
Dupilumab subgroup responder analysis: a post hoc analysis from LIBERTY PRIME and PRIME2 in prurigo nodularis.
+20 more products
+2 more
+2 more
+1 more
+2 more
+2 more
+1 more
+2 more
Recent R&D restructuring is a red flag for further consolidation; early-career scientists should assess program stability before accepting offers.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo